Biliary Tract Cancer

New Protocol: Tucatinib and Trastuzumab in her2-Positive Biliary Tract Cancer

2023-06-24

  • Study

    Phase II, basket study (SGNTUC-019)
    Previously treated with and progressed after ≥1 line of systemic therapy for HER2-positive metastatic disease.
    Tucatinib (TUC) + Trastuzumab (Tras) q21 (n=30)


  • Efficacy

    cORR: 46.7% [14 of 30 pts]
    CR: 0.03% [1 of 30 pts]
    mDOR: 6.0 mos [5.5-NR]
    mPFS: 5.5 mos [3.9-8.1]
    12-year OS: 53.8% [35.2-69.1]


  • Safety

    Any Grade: pyrexia (43.3%) and diarrhea (40.0%)
    Two (6.7%) pts discontinued TUC due to TEAEs, cholangitis and liver disorder.



    • Journal of Clin Oncol 2023 41:16_suppl, 4007-4007

    Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study

    http://doi.org/10.1200/JCO.2023.41.16_suppl.4007

    Reviewed by Elvin Chalabiyev, MD on Jun 24, 2023